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Adaptation of the Human Immunodeficiency Virus Type 1 Envelope
Glycoproteins to New World Monkey Receptors䌤
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Human immunodeficiency virus type 1 (HIV-1) infection encounters an early block in the cells of New World
monkeys because the CD4 receptor does not efficiently support HIV-1 entry. We adapted HIV-1(NL4-3) and
HIV-1(KB9), two HIV-1 variants with different envelope glycoproteins, to replicate efficiently in cells expressing
the CD4 and CXCR4 proteins of the common marmoset, a New World monkey. The HIV-1(NL4-3) adaptation
involves three gp120 changes that result in a specific increase in affinity for the marmoset CD4 glycoprotein.
The already high affinity of the HIV-1(KB9) envelope glycoproteins for marmoset CD4 did not significantly
change as a result of the adaptation. Instead, changes in the gp120 variable loops and gp41 ectodomain
resulted in improved replication in cells expressing the marmoset receptors. HIV-1(KB9) became relatively
sensitive to neutralization by soluble CD4 and antibodies as a result of the adaptation. These results demonstrate the distinct mechanistic pathways by which the HIV-1 envelope glycoproteins can adapt to less-thanoptimal CD4 molecules and provide HIV-1 variants that can overcome some of the early blocks in New World
monkey cells.

exhibits many similarities to HIV-1 infection of humans, making this model useful for studies of prophylaxis and pathogenesis. However, the inability of many HIV-1-directed modalities
to interfere with SIV infection has prompted the development
of chimeric simian-human immunodeficiency viruses (SHIVs).
SHIVs contain elements of HIV-1 (e.g., reverse transcriptase
(RT) or envelope glycoproteins) in an SIV genetic background. Some SHIVs replicate and cause AIDS-like disease in
macaques (20, 42). Nonetheless, because many antiviral agents
and immune responses are directed against HIV-1 elements
not included in the available SHIV chimerae, the development
of new animal models involving infection with more complete
HIV-1-like viruses is a worthy goal.
To this end, the infection of New World monkeys by HIV-1
has been investigated. The early postentry barriers to HIV-1
infection found in Old World monkeys are not present in the
cells of most New World monkeys. The principal early block to
HIV-1 infection in New World monkey cells occurs at the level
of virus entry (19, 30, 44). HIV-1 entry involves the viral gp120
(SU) and gp41 (TM) envelope glycoproteins, which are organized into trimers on the virion surface (6, 13, 48, 52). The
binding of gp120 to CD4 allows the interaction of gp120 with
one of two chemokine receptors, CCR5 or CXCR4. Receptor
binding triggers additional conformational changes in the
HIV-1 envelope glycoproteins that promote the fusion of the
viral and target cell membranes. The CXCR4 molecule of New
World monkeys such as squirrel monkeys and common marmosets can act as an efficient receptor for HIV-1; by contrast,
CD4 and CCR5 from these species do not effectively bind
HIV-1 gp120, leading to an entry block (19, 30, 44). The discrete nature of the early replication block in these New World
monkeys and the partial functionality of the common marmoset receptors raised the possibility that this barrier might be

The primate lentiviruses include the human immunodeficiency virus (human immunodeficiency virus type 1 [HIV-1]
and HIV-2) and simian immunodeficiency virus (SIV). In nature, HIV-1 and HIV-2 infect humans, HIV-1-related SIVcpz
viruses infect chimpanzees, and SIV variants infect African
monkeys (3, 16, 31, 32). Humans infected with HIV-1 and
HIV-2 and Asian macaques infected by certain SIVs and
HIV-2 often develop life-threatening immunodeficiency (AIDS)
due to depletion of CD4-positive T lymphocytes (3, 9, 11, 14,
16, 21).
Animal models of HIV-1 infection and disease have been
used to study viral pathogenesis and to test antiviral therapies
and vaccines. Current animal models of HIV-1 infection have
limitations. Chimpanzees can be infected with HIV-1 and the
closely related SIVcpz. However, chimpanzees are an endangered species, are prohibitively expensive, and are available
only in limited numbers (35). Moreover, HIV-1-infected chimpanzees rarely progress to AIDS-like disease (1, 4, 15, 37,
38, 47).
Old World monkeys can be naturally infected with various
SIV strains, including close relatives of HIV-2. By contrast, the
cells of most Old World Monkeys exhibit a postentry block to
HIV-1 infection that targets the viral capsid and is mediated by
TRIM5␣ (19, 39). The infection of Asian macaques by SIV
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overcome by direct adaptation of the virus. Here, starting with
two different HIV-1 isolates with distinct envelope glycoproteins, we derived and characterized virus variants able to enter
cells by using common marmoset (Callithrix jacchus) CD4 and
CXCR4 as receptors.
MATERIALS AND METHODS
Cell lines and antibodies. 293T and Cf2Th cells were obtained from the
American Type Culture Collection and maintained in Dulbecco’s modified Eagle
medium containing 10% fetal bovine serum (DMEM-10).
To generate Cf2Th cell lines stably expressing CXCR4, cells were transfected
with pcDNA3.1/Hygro(⫹) expressing human or common marmoset CXCR4.
Clones were selected in DMEM-10 supplemented with 200 g/ml of hygromycin
B (Roche). Cells expressing high levels of CXCR4 (Cf2Th-CXCR4hi) were
enriched by fluorescence-activated cell sorting with the 12G5 anti-CXCR4
monoclonal antibody (Pharmingen). Cells expressing CD4 and CXCR4 (Cf2ThCD4/CXCR4) were generated by transfecting the Cf2Th-CXCR4hi cells with
pZeoSV2(⫹) expressing human or common marmoset CD4. Clones were selected in DMEM-10 supplemented with 200 g/ml of zeocin (Invitrogen) and
200 g/ml of hygromycin B. Single clones of cells expressing human or common
marmoset CD4 and CXCR4 (Cf2Th-HuCD4/CXCR4 or Cf2Th-CjCD4/CXCR4,
respectively) were obtained by limiting serial dilution. Expression of CD4 and
CXCR4 was determined by flow cytometry with the Q4120 and 12G5 antibodies,
respectively.
Soluble CD4 (sCD4) and the neutralizing antibody 1121 were purchased from
ImmunoDiagnostics, Inc. The 1121 antibody recognizes the third variable (V3)
loop of HIV-1 gp120. The neutralizing monoclonal antibody immunoglobulin
G1b12 (IgG1b12), which recognizes a conserved gp120 epitope near the CD4binding site, was a kind gift of D. Burton (The Scripps Research Institute). The
C11 antibody, which recognizes the gp41-interactive N- and C-terminal regions
of gp120, was obtained from J. Robinson (Tulane Medical Center). M. Posner
(Dana-Farber Cancer Institute) provided the F105 antibody directed against the
CD4-binding site of HIV-1 gp120. The 2F5 antibody, which recognizes the
membrane-proximal region of gp41, was supplied by H. Katinger (Vienna, Austria). The CXCR4 inhibitor AMD3100 (bicyclam JM-2987) (5, 10, 18) was
obtained though the NIH AIDS Research and Reference Reagent Program.
Virus replication. Replication-competent HIV-1 viruses were generated by
transfecting 20 g of the pNL4-3 plasmid, which contains an infectious HIV1NL4-3 provirus (33), or 20 g of the pNL4-KB9 plasmid, which contains the KB9
envelope in an NL4-3 proviral background, into 2 ⫻ 106 293T cells using the
calcium phosphate transfection method (Invitrogen). Forty-eight hours after
transfection, supernatants containing these viruses [herein designated HIV1(NL4-3) and HIV-1(KB9), respectively] were harvested and cleared by lowspeed centrifugation. The level of virus in the supernatant was determined by
measuring RT, as described previously (43).
Cells were infected with 3,000 RT units for 14 h and then washed once with
phosphate-buffered saline (PBS). Every 3 or 4 days, cell supernatants were
removed and used for RT assays. Cells were trypsinized, diluted 1:10 in fresh
medium, and replated.
Analysis of env sequences. The envelope genes of the adapted viruses were
amplified by PCR of genomic DNA isolated from infected cells with the QIAamp
DNA blood minikit (QIAGEN). A 2.7-kb fragment containing the full env
sequence was generated by PCR with PfuUltra High-Fidelity DNA polymerase
(Stratagene) and the primers Env-forward (5⬘-GATAGAATTCAAGAGCAGA
AGACAGTG-3⬘) and Env-reverse (5⬘-TTTCTAGGTCTCGAGATACTGCTC3⬘) with EcoRI and XhoI restriction sites (marked in italics), respectively. The
2.7-kb fragment was cloned into the pcDNA3.1/Zeo(⫹) plasmid (Invitrogen) in
the case of HIV-1(NL4-3) adaptation or into pCR4blunt-TOPO (Invitrogen) in
the case of HIV-1(KB9) adaptation. The inserts from three to five individual
clones were sequenced to obtain the consensus sequence in the envelope region
of the adapted virus.
Site-directed mutagenesis. The sequence changes in env associated with viral
adaptation to common marmoset receptors were introduced individually or in
combination into the pSVIIIenv-NL4-3 or pSVIIIenv-KB9 plasmid expressing
the full-length HIV-1(NL4-3) or HIV-1(KB9) envelope glycoprotein, respectively, by site-directed mutagenesis using the QuikChange II XL site-directed
mutagenesis protocol (Stratagene). The presence of the desired mutations was
determined by automated DNA sequencing.
env complementation assay. Envelope complementation assays were performed using HIV-1 viruses capable of only a single round of infection, as
reported previously (23). Briefly, recombinant luciferase-expressing HIV-1 vi-

347

ruses (17) were generated by transfecting 293T cells with 4 g of the pSVIIIenv
plasmid expressing the HIV-1 envelope glycoproteins of interest, 4 g of the
pCMV⌬P1⌬envpA packaging plasmid, and 12 g of an HIV-1 vector plasmid,
using the calcium phosphate transfection method (Invitrogen). The HIV-1 vector
plasmid expresses an RNA that can be packaged into virions, reverse transcribed,
and integrated into a target cell, where it encodes firefly luciferase. Forty-eight
hours after transfection, supernatants containing reporter viruses were harvested
and cleared by low-speed centrifugation. The amounts of virus in the supernatants were quantified by measuring RT activity.
Target cells were seeded at a density of 6,000 cells/well in 96-well luminometer-compatible tissue culture plates. Twenty-four hours later, medium was
changed and 50,000 RT units of viruses were added to the cells. After 14 h of
incubation, the supernatant was removed and fresh medium was added. Fortyeight hours later, the medium was removed and cells were lysed with 30 l of
passive lysis buffer (Promega). Luciferase activity was measured using an EG&G
Berthold LB 96V microplate luminometer in accordance with the luciferase
assay system technical bulletin from Promega. For neutralization assays, the
viruses were incubated for 1 h at room temperature with the antibody or the
inhibitor before being added to the target cells.
HIV-1 gp120-CD4 binding assays. The expression of HIV-1 gp120 glycoproteins was achieved in 293T cells transfected with pSVIIIenv plasmids in which a
stop codon had been introduced in the region encoding the gp120-gp41 junction
and a plasmid expressing the HIV-1 Tat protein. The media containing gp120
proteins were harvested 48 h after transfection, and gp120 proteins were purified
by immunoaffinity chromatography using an IgG1b12-Sepharose column. The
purity and concentration of gp120 proteins were determined by Coomassie
staining of sodium dodecyl sulfate (SDS)-polyacrylamide gels and measurement
of absorbance at 280 nm, respectively.
Different concentrations of purified gp120 proteins were incubated for 1 h at
room temperature with 2 ⫻ 106 Cf2Th cells stably expressing either human or
marmoset CD4 in a total volume of 50 l of PBS containing 5% fetal bovine
serum (FBS). The cells were then washed once with PBS–5% FBS and resuspended in 50 l of PBS–5% FBS containing 3 g of the C11 anti-gp120 monoclonal antibody. The cell-antibody mixtures were incubated 45 min at room
temperature, washed once with PBS–5% FBS, and resuspended in 20 l of
PBS–5% FBS containing 1 l of anti-human phycoerythrin-conjugated IgG
(Jackson ImmunoResearch Laboratories). After 30 min of incubation, cells were
washed twice and analyzed by fluorescence-activated cell sorting using a Beckman flow cytometer.
Processing and subunit association of envelope glycoproteins. Cf2Th cells
were transfected with the pSVIIIenv plasmid and a plasmid expressing the HIV-1
Tat protein using Lipofectamine 2000 (Invitrogen). Six hours after transfection,
the medium was changed to a cysteine/methionine-free medium and the cells
labeled with 200 Ci of [35S]cysteine/methionine labeling mixture for approximately 16 h. The cell culture medium was cleared by centrifugation at 2,000 rpm
for 10 min at 4°C. Cells were washed with PBS and lysed with 1 ml of lysis buffer
(20 mM Tris [pH 7.5], 150 mM NaCl, 5 mM EDTA, 1% Igepal CA-630, and 1⫻
protease inhibitor cocktail) for 1 h at 4°C. Cell debris was removed by centrifugation at 16,000 ⫻ g for 30 min at 4°C. The total amount of protein in the
cleared cell lysates was normalized by measuring cpm of radioactivity. Immunoprecipitations were carried out in a total volume of 1 ml by incubating the cleared
cell lysates or culture medium with 15 l of protein A-Sepharose CL-4B beads
(Amersham Biosciences) and 3 l of a pool of sera from HIV-1-infected individuals. After two washes with 1 ml of lysis buffer, the beads were resuspended
in 35 l of 1⫻ lithium dodecyl sulfate loading buffer with 5% ␤-mercaptoethanol
and boiled for 5 min. Samples were analyzed on a 4 to 12% SDS-polyacrylamide
gel (Bis-Tris NuPAGE; Invitrogen).
Molecular modeling and energy calculations. All protein modeling and energy
calculations were performed on the Discovery Studio platform (Accelrys Software, Inc.). Protein modeling was based on protein sequence homology and
alignment with proteins of known structure, using the Modeler (version 9)
program in the Accelrys software package. Modeling of the NL4-3 gp120 core
was based on the structure of the HXBc2 HIV-1 gp120 core (91.2% sequence
identity). The V4 variable loop was specifically refined by the Loop Refinement
Program in Modeler. The model of domains 1 and 2 of common marmoset CD4
was based on the structure of these domains in human CD4 (sequence identity,
72.4%). The structure of the NL4-3 gp120 core in complex with marmoset
two-domain CD4 was derived by superposition of the modeled NL4-3 gp120 core
and marmoset CD4 onto the HXBc2 gp120 core and human CD4, respectively,
in the HXBc2 gp120 core/human two-domain CD4/17b Fab complex (1G9M).
The C␣ atom root mean squared deviations of the NL4-3 gp120 core and
marmoset CD4 from their respective reference structures were 0.29 and 0.30 Å.
Energies were calculated using the CHARMm (Chemistry at Harvard Mac-
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FIG. 1. Adaptation of HIV-1 for replication in cells expressing common marmoset CD4 and CXCR4. The indicated viruses were passaged in
Cf2Th-CjCD4/CXCR4 cells. The RT levels in the cell supernatants are shown as a function of the time after virus-cell incubation.

romolecular Mechanics) program (32b1). The energies of interaction between
gp120 core variants and marmoset CD4 were calculated after energy minimization and the introduction of solvent factors by use of the implicit of distancedependent dielectrics model. Every altered residue underwent side-chain refinement before energy minimization. Energy minimization was achieved in two
stages (the initial 1,000 steps on steepest descent, followed by an additional 2,000
steps on adopted basis NR).

RESULTS
Adaptation of HIV-1 for replication in cells expressing common marmoset receptors. With the ultimate goal of obtaining
an HIV-1 virus able to infect New World monkey cells, we have
adapted two different HIV-1 isolates, HIV-1(NL4-3) and HIV1(KB9), to use common marmoset CD4 and CXCR4 for virus
entry. HIV-1(NL4-3) has envelope glycoproteins derived from
an X4 HIV-1 isolate that was passaged in tissue-cultured cell
lines. HIV-1(KB9) is identical to HIV-1(NL4-3) except that its
envelope glycoproteins are those of SHIV(KB9). SHIV(KB9)
is an R5X4, neutralization-resistant virus derived by passage of
SHIV(89.6) in monkeys (22, 42). The adaptation of HIV1(NL4-3) and HIV-1(KB9) was achieved in canine Cf2Th thymocytes stably expressing human or common marmoset CD4
and CXCR4; efficient HIV-1 replication in Cf2Th cells requires expression of primate chemokine receptors (7, 25, 30).
To adapt HIV-1 to replicate in Cf2Th cells expressing marmoset receptors, we utilized a protocol previously employed to
adapt HIV-1 to replicate in CD4-negative cells (25). First, a
50:50 mixture of Cf2Th cells expressing human or marmoset
CD4 and CXCR4 receptors was infected with a stock of either
HIV-1(NL4-3) or HIV-1(KB9) prepared by transfection of
293T cells (see Materials and Methods). Viral replication was
determined by measuring RT activity in the supernatant of the
Cf2Th cultures every 2 to 3 days. In both cases, a peak of RT
activity was observed 8 to 10 days after infection, followed by
cell death and a drop in RT activity in the supernatant. However, a few days later, the cells started to recover and the RT
levels in the supernatants increased. RT activity reached a new
peak around 26 to 30 days after infection. Culture supernatants
at the time of these second peaks of RT activity were collected
and used to infect Cf2Th-CjCD4/CXCR4 cells. In the case of
viruses derived from the HIV-1(NL4-3) infection, the RT
counts in the supernatant of these cultures remained at background levels for several days; the RT counts started to rise at
day 13 after infection and reached a peak at about day 26. The

virus stock from this day will be referred to as the first passage
of the adapted HIV-1(NL4-3) virus. Adaptation of the HIV1(KB9) viruses to cells expressing the marmoset receptors occurred more rapidly than the adaptation of the HIV-1(NL4-3)
viruses. By 4 days after infection, the RT levels in the culture
started to increase, reaching a peak at about day 13. The virus
stock from this day will be referred to as the first passage of the
adapted HIV-1(KB9) viruses. To attempt to obtain more-robust HIV-1 replication in cells expressing marmoset receptors,
we continued passaging these adapted viruses in Cf2ThCjCD4/CXCR4 cells. As shown in Fig. 1, the kinetics of virus
replication improved after five and three passages of the HIV1(NL4-3) and HIV-1(KB9) viruses, respectively.
Analysis of env sequences of the adapted viruses. Virus adaptation to the Cf2Th cells expressing marmoset receptors
could involve multiple changes throughout the HIV-1 genome;
because we were specifically interested in understanding adaptation to the heterologous CD4 and CXCR4 proteins, we focused on the changes in the envelope glycoproteins of the
adapted viruses. The env sequences of the adapted viruses were
examined by PCR amplification of the genomic DNA of cells
from the day when the supernatant RT activity reached a
maximum. The amplified env DNA from each passage was
cloned in a sequencing vector, and three to five clones derived
from each passage were sequenced. The Env amino acid
changes associated with adaptation to the common marmoset
receptors CD4 and CXCR4 are summarized in Table 1. In
addition to the Env changes shown in Table 1, a few other
changes were observed in some individual clones but were not
maintained in subsequent passages; hence, these changes are
not likely to be important to the adaptation.
After the first passage of HIV-1(NL4-3), all of the sequenced clones exhibited a conversion of serine 334 to asparagine and serine 398 to asparagine. These two changes were
maintained in successive passages. Serine 334 is located at the
base of the V3 loop of gp120; the S334N change eliminates an
N glycosylation site at asparagine 332. Serine 398 is located in
the base of the V4 variable loop of gp120, and its change to
asparagine does not modify the glycosylation state of gp120.
During the second passage of HIV-1(NL4-3), a new mutation
that changes valine 242 in gp120 to isoleucine was introduced
into the viral genome. In the third passage, we observed an
additional change of alanine 281, a gp120 residue that makes
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TABLE 1. Amino acid changes in HIV-1 envelope glycoproteins associated with adaptation to common marmoset receptorsa
Virus

Predicted amino acid
change(s) in Env

Frequency of change in passage of adapted virus
Env region
1st

2nd

3rd

4th

5th

5/5
5/5
5/5
5/5
1/5

5/5
5/5
5/5
5/5
5/5

HIV-1(NL4-3)

V242I
A281V
S334N
S398N
A612T

C2 (gp120)
C2 (gp120)
V3 base (gp120)
V4 base (gp120)
Loop (gp41)

0/5
0/5
5/5
5/5
0/5

1/3
0/3
3/3
3/3
0/3

5/5
4/5
5/5
5/5
0/5

HIV-1(KB9)

E151K/E172K
F176Y
A561T

V1/V2 (gp120)
V1/V2 (gp120)
HR1 (gp41)

3/5
2/5
3/5

2/5
2/5
5/5

2/5
3/5
5/5

a
The frequency of the change is expressed as the number of clones in which the change is found per total number of clones sequenced. Amino acid residue numbers
are reported based on alignment with the prototypic HXBc2 sequence, as per current recommendations (26).

direct contact with CD4 (28, 29), to valine. Finally, alanine 612,
in the gp41 ectodomain, was converted to threonine during the
fourth passage. These five changes (S334N, S398N, V242I,
A281V, and A612T) were present in all clones of the HIV1(NL4-3) virus derived from the fifth passage.
The Env changes identified in the adaptation of HIV1(KB9) (Table 1) were located in the V1 and V2 variable loops
of gp120 and in heptad repeat 1 (HR1) of gp41; notably, the
location of these changes on the envelope glycoproteins was
very different from that of the changes found upon adaptation
of HIV-1(NL4-3). After the first passage, three of the five
sequenced clones contained the double changes E151K and
E172K and two other clones contained the change F176Y in
the V1 and V2 loops. These changes were preserved in subsequent passages, with the exception of one clone derived from
the second passage that contained the double change E153K/
I154M, also located in the V1/V2 loop (data not shown). The
change A561T in HR1 of gp41 was observed in three of five
clones derived from the first passage; all of the sequenced
clones exhibited this change following an additional passage of
the virus.

Influence of envelope glycoprotein changes in the adapted
viruses on entry into cells expressing human or marmoset
CD4 and CXCR4. The contribution of the observed envelope
glycoprotein changes to the ability of the virus to utilize marmoset CD4 and CXCR4 for entry into cells was examined
using an envelope complementation assay. The env changes
that arose during the adaptation were introduced alone or in
various combinations into pSVIIIenv plasmids that express the
wild-type NL4-3 or KB9 envelope glycoproteins. Recombinant
HIV-1 viruses encoding firefly luciferase and pseudotyped with
these envelope glycoprotein variants were incubated with
Cf2Th cells expressing human or marmoset CD4 and CXCR4.
Measurement of relative luciferase units in the target cells
provided an indication of the efficiency with which a single
round of infection occurred. Thus, the relative efficiency with
which different envelope glycoprotein variants utilize either
human or marmoset receptors to mediate virus entry can be
assessed. Because of potential quantitative and qualitative differences between human and marmoset CD4/CXCR4 expression in the two target cell lines, we refrain from comparing the

FIG. 2. Ability of wild-type and variant envelope glycoproteins to complement virus entry in cells expressing human CD4/CXCR4 (gray bars)
or marmoset CD4/CXCR4 (black bars). HIV-1 vectors encoding luciferase and pseudotyped with the indicated envelope glycoproteins derived
from HIV-1(NL4-3) (A) or HIV-1(KB9) (B) were incubated with cells for 14 h at 37°C. After washing and 48 h of culturing, the cells were lysed
and assayed for luciferase activity. RLU, relative luciferase units. The results shown are representative of three independent experiments. The
values shown are the means of three data points from a single experiment, and the error bars represent the standard deviations.
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FIG. 3. Replication of adapted viruses in cells expressing common marmoset CD4 and CXCR4. Cf2Th-CjCD4/CXCR4 cells were infected with
40,000 cpm of RT of either HIV-1(NL4-3) (A) or HIV-1(KB9) (B) viruses carrying the indicated envelope glycoprotein variants. The RT activity
in the culture supernatants was determined at the indicated times. The results shown are representative of two independent experiments. The RT
counts were at background levels for the NL4-3 wild-type (wt) and S334N/S398N virus variants and for the KB9 wt, E151K, E172K, F176Y, and
A561T virus variants (open symbols).

relative efficiencies with which human and monkey receptors
support the entry of any particular virus variant.
Figure 2A shows the luciferase activity in cells incubated
with recombinant HIV-1(NL4-3) variants. Some NL4-3 variants, particularly those containing the S334N change, supported slightly decreased entry into cells expressing human
receptors compared with that of the wild-type NL4-3 envelope
glycoproteins. The S398N and A612T changes did not increase
the efficiency of entry into cells expressing the marmoset receptors. However, the S334N change, which appeared during
the first passage, and the V242I change, which appeared during
the second passage, enhanced the efficiency of entry into
Cf2Th-CjCD4/CXCR4 cells by two- to threefold. The A281V
change raised the efficiency of entry into cells expressing the
marmoset receptors by about sixfold compared to that of the
wild-type NL4-3 envelope glycoproteins. The highest efficiency
of entry using the marmoset receptors (⬃11-fold increase) was
observed with the V242I/A281V double mutant. However, virus entry was less efficient for envelope glycoproteins in which
these two changes were combined with some of the other Env
changes.
The results obtained with HIV-1(KB9) variants are shown in
Fig. 2B. The ability of the envelope glycoproteins with the
single changes E151K and E172K to support entry into cells
expressing marmoset receptors was increased over that of the
wild-type KB9 envelope glycoproteins. Entry of the E151K/
E172K double mutant in Cf2Th-CjCD4/CXCR4 cells was
more than 23-fold greater than that observed for the wild-type
KB9 virus. Though the A561T change alone only minimally
increased entry into cells expressing the marmoset receptors,
when it was combined with the E151K/E172K or F176Y
change, severalfold increases in the efficiency of entry resulted.
This was especially striking in the case of the F176Y variant,
which on its own exhibited low levels of entry into cells expressing either human or marmoset receptors. These results
suggest that a subset of the amino acid changes acquired in the
envelope glycoproteins as a consequence of adaptation to cells
expressing marmoset CD4 and CXCR4 increase the ability of

the virus to enter cells by using the marmoset receptors. Several of the observed changes (E172K, F176Y, and E151K/
E172K) also decreased the efficiency with which viruses infected cells expressing human receptors.
Replication of adapted viruses in cells expressing marmoset
CD4 and CXCR4. To determine whether the adaptation-associated envelope glycoprotein changes were sufficient to allow
the virus to replicate efficiently in Cf2Th cells expressing
marmoset CD4 and CXCR4, we introduced the env changes
into replication-competent HIV-1 proviruses containing
wild-type HIV-1(NL4-3) and HIV-1(KB9) env genes. Viruses generated by transfection of these proviruses were
used to infect Cf2Th-CjCD4/CXCR4 cells (Fig. 3). The
HIV-1(NL4-3) and HIV-1(KB9) parental viruses were not
able to infect the Cf2Th-CjCD4/CXCR4 cells, although they
were able to infect Cf2Th-HuCD4/CXCR4 cells efficiently
(not shown). All of the variant viruses tested, with the exception of the F176Y variant, also replicated efficiently in cells
expressing the human receptors. Several of the HIV-1(NL4-3)
and HIV-1(KB9) variants supported very effective replication
in Cf2Th-CjCD4/CXCR4 cells. These variants corresponded
to those that exhibited a high level of complementation of the
single-round infection of env deletion viruses in the assay described above. Thus, some combinations of the observed
envelope glycoprotein changes are sufficient to confer an improved ability to support infection of cells expressing marmoset CD4 and CXCR4.
Binding of gp120 glycoproteins from adapted viruses to human and marmoset CD4. To determine if the improved ability
of some envelope glycoproteins from the adapted viruses to
infect cells expressing the marmoset receptors was due to an
increase in the affinity of gp120 for marmoset CD4, we studied
the binding of soluble gp120 variants to human or marmoset
CD4 expressed on the surfaces of cells. Bound gp120 was
detected by the C11 anti-gp120 antibody, which recognizes an
epitope involving the N and C termini of gp120, and antihuman phycoerythrin-conjugated IgG. None of the adaptationassociated changes in the HIV-1 envelope glycoproteins af-
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FIG. 4. Binding of wild-type and variant gp120 glycoproteins to human and marmoset CD4 expressed on the surface of Cf2Th cells. The binding
of soluble gp120 derived from HIV-1(NL4-3) (A) or HIV-1(KB9) (B) variants to the CD4-expressing cells was studied by using flow cytometry,
as described in Materials and Methods. MFI, mean fluorescence intensity. The results shown are representative of two or more independent
experiments.

fected recognition by the C11 antibody (data not shown). The
binding of the wild-type HIV-1(NL4-3) and HIV-1(KB9)
gp120 glycoproteins to control CD4-negative Cf2Th cells was
at the background of the assay, close to the value (mean fluorescence intensity ⫽ 1 to 2) observed with Cf2Th-CD4 cells
when gp120 was not included in the assay (data not shown).
Figure 4A shows the binding of HIV-1(NL4-3) gp120 variants
to human (left panel) or marmoset (right panel) CD4, and Fig.
4B shows the results for HIV-1(KB9) gp120 variants. In all
cases, the affinity for human CD4 was similar for the wild-type
and variant gp120 glycoproteins. In the case of NL4-3 variants,
we observed a good correlation between binding of gp120 to
marmoset CD4 and entry into cells expressing the marmoset
receptors. The wild-type and S398N NL4-3 gp120 glycoproteins exhibited a relatively low binding affinity for marmoset
CD4. S334N/S398N/V242I/A281V gp120 exhibited the highest
binding affinity for marmoset CD4, followed by the V242I/
A281V double mutant. The single changes A281V and S334N
improved the binding to marmoset CD4 by about twofold over
binding of wild-type NL4-3 gp120.
The binding of wild-type KB9 gp120 to common marmoset
CD4 was surprisingly efficient. This robust ability of KB9 gp120
to bind marmoset CD4 might be unusual, since the gp120 from
HIV-1(89.6), the parent of HIV-1(KB9), doesn’t bind efficiently to marmoset CD4 (data not shown). The E151K and

F176Y gp120 glycoproteins bound marmoset CD4 comparably
to binding of wild-type KB9 gp120, whereas the E172K and
E151K/E172K gp120 glycoproteins exhibited a slight but consistent increase in binding to marmoset CD4 relative to that of
KB9 gp120. Thus, the adaptation of HIV-1(NL4-3) involves an
increase in the low affinity of the gp120 glycoprotein for marmoset CD4, whereas the already efficient KB9 gp120 undergoes less of an increase in affinity for marmoset CD4 during
HIV-1(KB9) adaptation.
Processing and subunit association of envelope glycoproteins. The expression of wild-type and variant envelope glycoproteins was examined. The processing of the gp160 envelope
glycoprotein precursor of all of the HIV-1(NL4-3) variants was
efficient (Fig. 5, left panels). The processing of most of the
HIV-1(KB9) envelope glycoproteins was efficient, with the exception of the F176Y and F176Y/A561T envelope glycoproteins, the processing of which was markedly reduced compared
to that of the wild-type glycoprotein. Evaluation of the ratio of
gp120 associated with the cells and gp120 in the medium (Table 2) demonstrated that slight decreases in gp120-gp41 association were observed for a few mutants, which might explain
the lesser ability of these variants to complement virus entry in
Cf2Th-HuCD4/CXCR4 cells.
Neutralization sensitivities of Env mutants. Sensitivity to
inhibition by soluble CD4, neutralizing antibodies, and small-
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FIG. 5. Processing and subunit association of the wild-type and variant envelope glycoproteins. Cf2Th cells transfected with plasmids expressing
the indicated envelope glycoprotein variants were radiolabeled with [35S]cysteine/methionine for approximately 16 h. The cell supernatants and cell
lysates were immunoprecipitated with a pool of sera from HIV-1-infected individuals and analyzed by 4-to-12%-gradient SDS-polyacrylamide gel
electrophoresis. Similar results were obtained with 293T cells (data not shown).

molecule ligands of chemokine receptors can provide an indication of changes in the receptor-binding regions of the HIV-1
envelope glycoproteins (24, 41). We tested the sensitivities of
the envelope glycoprotein variants from the adapted viruses to
neutralization by different antibodies and compounds. Table 3
shows the concentration of antibody or inhibitor that reduces
the infection of Cf2Th-HuCD4/CXCR4 cells by 50%. The
HIV-1(NL4-3) variants were generally more sensitive to neutralization by antibodies and by sCD4 than the HIV-1(KB9)

variants. All of the HIV-1(NL4-3) variants exhibited similar
levels of sensitivity to neutralization by antibodies and sCD4,
with the mutants containing the V242I change exhibiting
slightly greater (⬃2-fold) sensitivity. As previously reported
(22), wild-type HIV-1(KB9) is very resistant to neutralization
by antibodies that bind gp120 (IgG1b12, F105, and 1121). The
changes in the HIV-1(KB9) envelope glycoproteins associated
with adaptation to marmoset receptors generally increased the
sensitivity to antibody and sCD4 neutralization. Thus, adapta-

TABLE 2. Phenotypes of HIV-1 envelope glycoprotein variants from viruses adapted to common marmoset receptors CD4 and CXCR4
Envelope variant

Wild-type NL4-3
NL4-3 variants
S334N
S398N
V242I
A281V
A612T
S334N/S398N
V242I/A281V
V242I/S334N/S398N
V242I/A281V/S334N/S398N
V242I/A281V/S334N/
S398N/A612T
Wild-type KB9
KB9 variants
E151K
E172K
F176Y
A561T
E151K/E172K
E151K/E172K/A561T
F176Y/A561T

gp160
processinga

Subunit
associationa

ⴙⴙⴙⴙ

ⴙⴙⴙⴙ

ⴙⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙ

ⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙ
ⴙⴙⴙ
ⴙⴙ
ⴙⴙ
ⴙⴙ

ⴙⴙ

ⴙⴙⴙ

ⴙⴙ
ⴙⴙ
ⴙ
ⴙⴙ
ⴙⴙ
ⴙⴙ
ⴙ

ⴙⴙⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙⴙⴙⴙ
ⴙⴙⴙⴙ
ⴙⴙ

Relative entry in
Cf2Th-CjCD4/
CXCR4 cellsb

1
3
0.38
3
6
0.03
3
11
3
6
6
1
5
8
0.02
2
23
62
41

Virus infectivity in
Cf2Th-CjCD4/
CXCR4 cellsc

Binding to
CjCD4d

⫺

ⴙ

ND
ND
ND
55
ND
⫺
26–29
ND
26–29
26–29

ⴙⴙ
ⴙ
ⴙ
ⴙⴙ
NA
ⴙⴙ
ⴙⴙⴙ
ⴙⴙ
ⴙⴙⴙ
NA

⫺

ⴙⴙⴙⴙ

⫺
⫺
⫺
⫺
29–39
12–15
12–15

ⴙⴙⴙⴙ
ⴙⴙⴙⴙⴙ
ⴙⴙⴙⴙ
NA
ⴙⴙⴙⴙⴙ
NA
NA

a
The efficiency of processing and subunit association are reported as follows: ⴙⴙⴙⴙⴙ, greater than 110% of level for wild-type NL4-3; ⴙⴙⴙⴙ, 90 to 110% of level
for wild-type NL4-3; ⴙⴙⴙ, 70 to 90% of level for wild-type NL4-3; ⴙⴙ, 50 to 70% of level for wild-type NL4-3; ⴙ, less than 50% of level for wild-type NL4-3.
b
The entry efficiency was determined as described in the legend to Fig. 2 and in Materials and Methods. The results are reported as n-fold increases with respect
to the levels of entry supported by the respective wild-type NL4-3 and KB9 envelope glycoproteins.
c
The infectivities of the viruses were determined as described in the legend to Fig. 3 and in Materials and Methods. The days when the RT activity level reached
a maximum are indicated. Lack of detectable virus replication is indicated by a minus sign. ND, not determined.
d
The binding of soluble gp120 to CjCD4 was determined as described in the legend to Fig. 4 and in Materials and Methods. More-efficient binding is expressed as
an increasing number of plus signs, with the “ⴙ” symbol indicating a binding affinity comparable to that of wild-type NL4-3 gp120 for CjCD4 and “ⴙⴙⴙⴙⴙ” indicating
a binding affinity comparable to that of wild-type NL4-3 gp120 for human CD4. NA, not applicable.
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TABLE 3. Neutralization of pseudotyped HIV-1 viruses by antibodies and entry inhibitors
IC50 (g/ml) ofa:
Envelope variant

Wild-type NL4-3
S334N
S398N
V242I
A281V
A612T
S334N/S398N
V242I/A281V
V242I/S334N/S398N
V242I/A281V/S334N/S398N
V242I/A281V/S334N/S398N/A612T
Wild-type KB9
E151K
E172K
F176Y
A561T
E151K/E172K
E151K/E172K/A561T
F176Y/A561T

IgG1b12 on
CD4BS gp120

F105 on
CD4BS gp120

1121 on V3
loop gp120

2F5 on gp41

sCD4 on
CD4-binding
site gp120

AMD3100 on
CXCR4

0.618 ⫾ 0.06
0.443 ⫾ 0.03
0.473 ⫾ 0.03
0.362 ⫾ 0.05
0.456 ⫾ 0.16
0.451 ⫾ 0.04
0.505 ⫾ 0.30
0.290 ⫾ 0.15
0.327 ⫾ 0.10
0.290 ⫾ 0.17
0.204 ⫾ 0.10
⬎25
⬎25
10.79 ⫾ 3.0
ND
⬎25
1.38 ⫾ 0.97
5.29 ⫾ 2.9
6.54 ⫾ 0.02

0.547 ⫾ 0.26
0.504 ⫾ 0.26
0.868 ⫾ 0.56
0.219 ⫾ 0.08
0.609 ⫾ 0.22
0.958 ⫾ 0.88
0.304 ⫾ 0.15
0.206 ⫾ 0.12
0.306 ⫾ 0.09
0.246 ⫾ 0.07
0.384 ⫾ 0.34
⬎10
⬎10
⬎10
ND
⬎10
⬃10
⬃10
3.62 ⫾ 0.40

0.124 ⫾ 0.09
0.074 ⫾ 0.05
0.144 ⫾ 0.15
0.089 ⫾ 0.06
0.227 ⫾ 0.16
0.273 ⫾ 0.37
0.062 ⫾ 0.03
0.086 ⫾ 0.05
0.068 ⫾ 0.04
0.045 ⫾ 0.02
0.059 ⫾ 0.03
⬎10
⬎10
1.93 ⫾ 1.7
ND
⬎10
0.400 ⫾ 0.55
0.509 ⫾ 0.74
0.025 ⫾ 0.03

1.310 ⫾ 0.89
0.728 ⫾ 0.68
1.290 ⫾ 1.32
0.387 ⫾ 0.25
1.474 ⫾ 1.01
1.257 ⫾ 0.68
1.268 ⫾ 0.22
0.257 ⫾ 0.15
0.354 ⫾ 0.21
0.309 ⫾ 0.23
0.287 ⫾ 0.18
6.33 ⫾ 5.2
7.44 ⫾ 3.6
0.287 ⫾ 0.12
ND
0.702 ⫾ 0.31
0.575 ⫾ 0.60
0.469 ⫾ 0.40
0.268 ⫾ 0.12

0.536 ⫾ 0.11
0.328 ⫾ 0.07
0.599 ⫾ 0.08
0.287 ⫾ 0.17
0.415 ⫾ 0.14
0.490 ⫾ 0.16
0.371 ⫾ 0.16
0.243 ⫾ 0.11
0.223 ⫾ 0.10
0.270 ⫾ 0.13
0.222 ⫾ 0.06
1.13 ⫾ 0.36
0.819 ⫾ 0.53
0.262 ⫾ 0.12
ND
1.08 ⫾ 0.65
0.225 ⫾ 0.06
0.287 ⫾ 0.26
0.194 ⫾ 0.09

0.012 ⫾ 0.005
0.007 ⫾ 0.002
0.014 ⫾ 0.003
0.015 ⫾ 0.006
0.010 ⫾ 0.002
0.014 ⫾ 0.002
0.007 ⫾ 0.001
0.010 ⫾ 0.006
0.011 ⫾ 0.009
0.012 ⫾ 0.011
0.008 ⫾ 0.002
0.021 ⫾ 0.012
0.013 ⫾ 0.004
0.004 ⫾ 0.000
ND
0.006 ⫾ 0.005
0.005 ⫾ 0.002
0.007 ⫾ 0.004
0.008 ⫾ 0.002

a
Each IC50 represents the concentration of antibody or inhibitor resulting in a 50% reduction in a single-round infection of Cf2Th-HuCD4/CXCR4 cells. The values
shown are means from three independent experiments done in duplicate ⫾ standard deviations. ND, not determined. The target on gp120, gp41, or CXCR4 and the
antibody/inhibitor are indicated. CD4BS, CD4-binding site epitope on gp120.

tion to marmoset receptors resulted in an increase in sensitivity
to neutralization by antibodies and sCD4 for HIV-1(KB9) but
not for HIV-1(NL4-3).
The low affinity of X4 or R5X4 gp120 glycoproteins for
CXCR4 can make accurate assessment of CXCR4-binding
ability difficult. Since differences in chemokine receptor-directed binding affinity result in different sensitivities of virus
infection to chemokine receptor-directed ligands (41), we investigated the effect of AMD3100, a CXCR4 ligand, on the
infection of cells by viruses with the variant envelope glycoproteins. Viruses with all of the HIV-1(NL4-3) envelope glycoprotein variants exhibited similar sensitivities to AMD3100
(Table 3).
Infection of Cf2Th-HuCD4/CXCR4 cells by viruses with the
wild-type KB9 envelope glycoproteins was inhibited by
AMD3100 at concentrations similar to those observed for infection by viruses with the NL4-3 envelope glycoproteins (Table 3). The adaptation-associated changes in the KB9 gp120
V1/V2 variable loops and gp41 ectodomain resulted in a twoto fivefold increase in sensitivity to AMD3100. Increased
AMD3100 sensitivity was observed even for changes, such as
E172K and A561T, that individually were not sufficient to
allow efficient replication in cells expressing the marmoset
receptors. Thus, increased AMD3100 sensitivity was associated
with HIV-1(KB9) virus adaptation but was insufficient to explain the increased ability to utilize marmoset receptors.
The above experiments were conducted using target cells
that express human CD4 and CXCR4. Although human and
marmoset CXCR4 proteins are 98% similar, HIV-1 adaptation
to cells expressing marmoset receptors might be specific
for marmoset CXCR4. Therefore, we tested the effect of
AMD3100 on the infection of cells expressing human CD4 and
marmoset CXCR4 (Table 4). Approximately 10-fold-lower

concentrations of AMD3100 were required to inhibit infection
of these cells by the viruses with the variant envelope glycoproteins compared with cells expressing human CD4 and human CXCR4. This result is consistent with lower affinities of
the envelope glycoproteins of the parental and adapted viruses
for the marmoset CXCR4 protein, relative to those for human
CXCR4. No increases were observed in the concentrations of
AMD3100 required to inhibit viruses with the adaptation-associated envelope glycoproteins compared with those required
to block infection of viruses with the parental envelope glycoproteins. We conclude that an increase in the affinity of the
HIV-1 envelope glycoproteins for marmoset CXCR4 is not
necessary for virus adaptation to cells expressing the marmoset
receptors.

TABLE 4. Neutralization of pseudotyped HIV-1 viruses by the
entry inhibitor AMD3100 in cells expressing human CD4
and common marmoset CXCR4
Envelope variant

IC50 (g/ml) of AMD3100
with cells expressing
CXCR4a

Wild-type NL4-3 ........................................................0.0012 ⫾ 0.0004
V2421/A281V .............................................................0.0013 ⫾ 0.0002
S334N/S398N/V242I/A281V.....................................0.0009 ⫾ 0.0003
S334N/S398N/V242I/A281V/A612T ........................0.0006 ⫾ 0.0002
Wild-type KB9 ...........................................................0.0022 ⫾ 0.0007
E151K/E172K.............................................................0.0009 ⫾ 0.0002
E151K/E172K/A561T ................................................0.0010 ⫾ 0.0004
F176Y/A561T .............................................................0.0013 ⫾ 0.0008
a
IC50s represent concentrations of AMD3100 resulting in a 50% reduction in
a single-round infection of Cf2Th-HuCD4/CjCXCR4 cells. Values shown are
means from four independent experiments done in duplicate ⫾ standard deviations.
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FIG. 6. Modeling the interaction of the adapted HIV-1(NL4-3)
gp120 core with marmoset CD4. The modeled NL4-3 gp120 core
(blue) bound to two-domain marmoset CD4 (magenta) is shown, with
the gp120 residues that changed during the adaptation indicated. Also
shown is phenylalanine 43 of CD4, which makes critical contributions
to gp120 binding (28, 29).

DISCUSSION
In this work, we adapted two different HIV-1 isolates, HIV1(NL4-3) and HIV-1(KB9), to replicate in cells using the common marmoset receptors CD4 and CXCR4. The analysis of
the envelope glycoproteins of the adapted viruses revealed that
in both cases a small number of changes that appeared during
the adaptation allowed the viruses to use the marmoset receptors to gain entry into the cells. Probably because of differences
in the phenotypes of the parental viruses, HIV-1(NL4-3) and
HIV-1(KB9) adapted to the marmoset receptors by distinct
mechanistic pathways. The genotypic and phenotypic properties of the adapted viruses are summarized in Table 2.
The changes that allow the HIV-1(NL4-3) virus to enter
cells expressing marmoset CD4 and CXCR4 involve gp120
residues 281, 334, and 242. The changes that appeared in these
residues during the adaptation increase the gp120 binding affinity for marmoset CD4 without a detectable effect on the
affinity for human CD4. In X-ray crystal structures of the
HIV-1 gp120-CD4 complex, alanine 281 makes direct contact
with CD4 (Fig. 6) (28, 29). Molecular modeling predicts that
the larger side chain of valine that was associated with adaptation makes better contact with CD4 and increases the gp120
binding affinity for marmoset CD4 (Table 5). The major differences between human and marmoset CD4 that impact
gp120 binding involve residues 48 and 59 in CD4 domain 1
(30). In human CD4, proline 48 contributes to a ␤-turn that
results in an antiparallel orientation of the C⬙ and D strands of
CD4, each of which makes important contacts with gp120 (29,
49). The replacement of proline 48 with a glutamine residue in
common marmoset CD4 might alter the ␤-turn and consequently affect the relationship of the C⬙ and D strands. The
S334N change in gp120 has been previously seen in an HIV-1
isolate adapted to replicate efficiently in cells expressing a
human CD4 mutant (K46D) with a low affinity for gp120 (8).
Residue 334 is located near the base of the V3 loop and
appears to be too far from the CD4 binding site to alter CD4
affinity directly; however, the resulting loss of a carbohydrate at
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asparagine 332 might change the conformation of the unliganded gp120 and thus indirectly increase CD4-binding ability
(Table 5). The V242I change alone increases the binding affinity of soluble gp120 for marmoset CD4 only minimally but
does contribute to marmoset CD4 binding in the context of the
A281V change. Valine 242 projects into a groove in gp120 that
has been proposed to make contact with gp41 and regulate
fusion efficiency (51). It is possible that the adaptation-associated change in valine 242 amplifies the impact of CD4 binding
on subsequent conformational changes required for virus entry. Consistent with this, the viruses containing the V242I
change exhibited a slight increase in sensitivity to neutralization by different antibodies (Table 3), possibly reflecting a
more activation/deactivation-prone state. In summary, most of
the HIV-1(NL4-3) adaptation-associated changes result in specific increases in binding to marmoset CD4, providing a natural
explanation of the adaptation.
The changes that evolved in the HIV-1(KB9) envelope glycoproteins as a consequence of the adaptation to cells expressing marmoset receptors differ in location and mechanistic consequences from those observed in the case of HIV-1(NL4-3).
One likely explanation for these differences lies in the already
high level of efficiency with which the parental KB9 gp120
glycoprotein binds marmoset CD4. One obvious reason for this
high binding affinity is that KB9 gp120 already has a valine at
residue 281, which the above studies with the NL4-3 gp120
variants demonstrate contributes to marmoset CD4 binding.
Of interest, the conversion of alanine 281 to valine occurred
during the in vivo passages of SHIV-89.6 in rhesus monkeys
that led to the generation of SHIV-KB9 (22). Previous work,
which we confirmed here, indicated that the KB9 gp120 glycoprotein binds human and rhesus monkey CD4 comparably to
binding of the 89.6 gp120 glycoprotein; however, KB9 gp120

TABLE 5. Modeling predictions of binding energies between HIV1(NL4-3) gp120 core variants and two-domain marmoset CD4a

HIV-1 gp120 core variants

Wild-type NL4-3
V242I
A281V
S334N
S398N
V242I ⫹ A281V
S334N ⫹ S398N
S334N ⫹ S398N ⫹ V242I
S334N ⫹ S398N ⫹ V242I ⫹
A281V
Wild-type NL4-3 ⫹
marmoset CD4 F43Ab

Total
interaction
energy
(kcal/mol)

van der
Waals
energy
(kcal/mol)

Electrostatic
energy
(kcal/mol)

⫺320.2
⫺318.5
ⴚ326.8
⫺323.5
⫺324.4
⫺326.7
⫺323.3
⫺323.8
⫺329.1

⫺104.5
⫺105.1
ⴚ107.1
⫺105.9
⫺106.4
⫺107.3
⫺106.2
⫺106.4
⫺108.1

⫺215.7
⫺213.4
ⴚ219.7
⫺217.7
⫺218.0
⫺219.4
⫺217.1
⫺217.4
⫺221.0

⫺305.7

⫺92.3

⫺213.4

a
As described in Materials and Methods, the interaction of the indicated
HIV-1(NL4-3) gp120 core with two-domain marmoset CD4 was modeled based
on a known structure of the HIV-1 gp120 core/human two-domain CD4 complex
(29). After energy minimization, the total interaction energy and the contributions of van der Waals and electrostatic interactions were calculated. Boldface
indicates the most favorable energy changes associated with the alteration of a
single residue.
b
As a control, the interaction of the wild-type NL4-3 gp120 core and the F43A
mutant of marmoset CD4 was modeled and used for the calculation of energy.
Changes in phenylalanine 43 of human CD4 significantly affect gp120 binding
(29).
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FIG. 7. Differences between human and common marmoset CD4. The primary amino acid sequences of the amino-terminal two domains of
human (Hu) and common marmoset (Cj) CD4 are aligned. Identical residues are shaded. Amino acid residues that exhibit differences in charge
between the two CD4 proteins are designated with an asterisk. Asterisk-marked residues buried in the HIV-1 gp120 core-CD4 interface are dotted;
asterisk-marked residues on the CD4 surface opposite to the expected positions of the gp120 V1/V2 loops are placed in parentheses. The image
shows the structure of the HIV-1 gp120 core (green) in complex with two-domain (D1D2) human CD4 (left) (28, 29). The location of the V1/V2
stem is indicated. The D1D2 CD4 basic surface residues are blue, and the acidic surface residues are red. The image on the right depicts the
modeled structure of HIV-1 gp120 complexed with marmoset two-domain CD4. The color scheme is identical to that used for the gp120-human
CD4 complex.

binds marmoset CD4 more efficiently than 89.6 gp120 (data
not shown). Thus, the differences between the 89.6 and KB9
gp120 glycoproteins, including the alanine-valine substitution
at residue 281, contribute to an increased binding affinity of
KB9 gp120 for common marmoset CD4 but not for human or
rhesus monkey CD4.
The adaptation-associated changes in the HIV-1(KB9) envelope glycoproteins involve the gp120 V1 and V2 variable
loops and the gp41 HR1 region. Presumably because the KB9
gp120 glycoprotein starts off with a relatively high affinity for
marmoset CD4, the adaptation-associated changes in the HIV1(KB9) envelope glycoproteins only minimally affect marmoset
CD4 binding. Only the V2 loop change, E172K, is associated
with a slight but specific increase in the affinity of gp120 for
marmoset CD4. How then do the observed adaptation-associ-

ated changes exert their dramatic impact on the ability of the
HIV-1(KB9) envelope glycoproteins to utilize marmoset receptors? One possibility that we considered is that the adapted
KB9 gp120 glycoprotein binds marmoset CXCR4 more efficiently. Although the gp120 V1/V2 and gp41 changes are not
expected to affect the CXCR4-binding region of gp120 directly,
they could hypothetically exert indirect effects. An increase in
affinity for CXCR4 predicts a decrease in sensitivity to the
CXCR4 ligand, AMD3100, which we did not observe. In fact,
the adaptation-associated changes resulted in a slightly increased sensitivity to AMD3100 for infection of cells bearing
human or marmoset CXCR4. Thus, an increase in affinity for
CXCR4 is an unlikely explanation for the HIV-1(KB9) adaptation to marmoset receptors.
An alternative explanation that is more consistent with the
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observations recognizes the high degree of resistance to neutralizing antibodies that the HIV-1(KB9) envelope glycoproteins achieved as a result of in vivo SHIV propagation in
monkeys. Resistance to neutralization by antibodies is often
accompanied by an increase in HIV-1 dependence on CD4 for
entry (27, 40, 45). Thus, as a result of in vivo requirements to
avoid neutralizing antibodies, the HIV-1(KB9) envelope glycoproteins may less efficiently undergo the requisite conformational changes for virus entry in response to nonoptimal CD4.
Even though the KB9 envelope glycoproteins bind marmoset
CD4 efficiently, minor differences in the interaction of CD4
and the gp120 variable loops, for example, could impact the
efficiency of entry. CD4 binding has been shown to reposition
the gp120 V1/V2 loops, promoting subsequent events in the
virus entry process (46, 50). These events may include chemokine receptor binding and gp41 conformational rearrangements. Although the structural details of V1/V2 loop interaction with CD4 are unknown, the surface of CD4 domains 1 and
2, which contains an abundance of charged residues, is likely
involved. In this light, it is intriguing that both of the KB9
V1/V2 alterations that contribute to marmoset CD4 adaptation involve a change in charge, from acidic glutamic acid
residues to basic lysine residues. Because at least 10 surfaceexposed residues potentially able to contact the V1/V2 gp120
loops differ in charge between human and marmoset CD4
domains 1 and 2 (Fig. 7), the charge changes in the adapted
KB9 gp120 V1/V2 loops may allow attractive or repulsive electrostatic forces to drive the appropriate loop movements in a
marmoset CD4-specific fashion. A salt bridge between lysine
172 and an acidic residue on the marmoset CD4 surface might
additionally contribute to the slight increase in binding affinity
observed for this variant. The decreased ability of KB9 envelope glycoproteins with some of V1/V2 loop changes to support entry into cells expressing human CD4 is consistent with
the above model. The adaptation-associated V1/V2 loop
changes, particularly E172K, also appear to disrupt interactions between elements on the unliganded KB9 trimer that
govern neutralization resistance, since the adapted virus envelope glycoproteins are much more susceptible to neutralization
by antibodies and sCD4.
The A561T change in the gp41 HR1 region contributes to a
two- to threefold improvement in the efficiency of infection of
cells expressing the marmoset receptors by HIV-1(KB9) viruses. This change did not alter the sensitivity of the virus to
antibodies or sCD4. The mechanism by which the A561T
change contributes to adaptation to marmoset receptors presumably involves promotion of entry-related conformational
events in the setting of nonoptimal receptor interactions. Of
interest, changes in the adjacent residue 560 have been associated with SIV macrophage tropism (34, 36), which involves
the ability to use the low levels of CD4 on the macrophage
surface more efficiently (2, 12). Both residues 560 and 561 are
located in the b and c positions, respectively, within the gp41
heptad repeat; the predicted surface exposure of these b and c
residues would allow interactions with other envelope glycoprotein elements either prior to or after formation of the gp41
six-helix bundle thought to represent the fusogenic conformation.
The derivation of HIV-1 envelope glycoprotein variants that
can efficiently use the common marmoset receptors CD4 and
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CXCR4 to enter cells advances efforts to overcome the major
early block to HIV-1 in these New World monkeys. The use of
these viruses should allow exploration of any additional blocks
to HIV-1 in these monkeys. Understanding and circumventing
these blocks may lead to novel animal models for study of
HIV-1 pathogenesis.
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